Sentences with phrase «immune checkpoint blockade therapy»

«While immune checkpoint blockade therapy is effective in many cancers, it has been less successful for this particular form of prostate cancer, which has motivated a search for targeted therapies that overcome this resistance.»

In a retrospective analysis of clinical trial data, they found that melanoma patients with highly aneuploid tumors were less likely to benefit from immune checkpoint blockade therapy than patients whose tumors showed fewer chromosomal disruptions.

Not exact matches

Researchers at The University of Texas MD Anderson Cancer Center developed a novel chimeric mouse model to test the combination therapy using immune checkpoint blockades with therapies targeting myeloid - derived suppressor cells (MDSCs).

One phase I trial of an immune checkpoint blockade drug combined with two established targeted therapies yielded 40 - 50 percent response rates among patients with metastatic kidney cancer.

Researchers found the gene therapy approach had stronger results when used in combination with either depletion of immunosuppressive cells from the tumor mass or with immune checkpoint blockade.

Checkpoint blockade therapy works by interfering with cancer's ability to turn off the body's immune reaction.

Checkpoint blockade therapy obstructs those signals, makes T - cells see the cancer cells as invaders again, and allows the immune system to do its job.

We also apply these techniques to model systems in order to identify subgroups of patients who are uniquely sensitive or resistant to targeted therapies, such as poly (ADP - ribose) polymerase (PARP) inhibitors or immune checkpoint blockade.

As demonstrated by the breadth of clinical trial involvement shown above, CCIR members are testing the utility of immune checkpoint blockade in lymphoma (shown by Dr. Allison to be effective against melanoma), genetic engineering in cell therapy (e.g., CD19, CXCR2, TGF - β DNR), and TLR agonists or IL - 2 in vaccine formulations as well as some novel combination therapies, such as the infusion of tumor - reactive lymphocytes from HLA - matched donors who were vaccinated with a lymphoma idiotype.

For their collective contributions to the pre-clinical foundation and development of immune checkpoint blockade, a novel form of cancer therapy that has transformed the landscape of cancer treatment.

In the next year, members of the Dream Team will continue to study the tumor microenvironment before and after checkpoint blockade, to develop algorithms to identify and predict the best antigens on cancer cells that can be used for cancer immunotherapies, to analyze tumor tissues and blood for biomarkers that will help in selecting patients who will benefit, and identifying the best approaches to increase the strength of immune cells for adoptive cell therapy.

In honor of James Allison, Lieping Chen, Gordon Freeman, Tasuku Honjo and Arlene Sharpe for contributions to the pre-clinical foundation and development of immune checkpoint blockade, a novel form of cancer therapy that has transformed the landscape of cancer treatment.

Mismatch repair (MMR)- deficient cancers have been discovered to be highly responsive to immune therapies such as PD - 1 checkpoint blockade, making their definition in patients, where they may be relatively rare, paramount for treatment decisions.

Low - dose chemotherapy, radiation, or targeted therapies given in combination with immune checkpoint blockade may prove to be an effective and efficient way to immunize the body against tumor cells,» says CRI Scientific Advisory Council associate director James P. Allison, Ph.D., who identified the first immune checkpoint blockade with his discovery in 1995 that the cytotoxic T lymphocyte antigen - 4 (CTLA - 4) receptor inhibited T cell responses.

In addition to checkpoint blockade antibodies, the editors also pointed to recent advances in adoptive cell therapy — removing a patient's immune cells, engineering them in the lab, and then re-infusing them back into the patient to fight cancer.

It is also the first in an emerging class of therapies called «checkpoint blockade,» which enhance the immune system's ability to attack cancer by interfering with immunological checkpoints that slow or stop immune cell activation and proliferation in the presence of tumors or chronic viral infection.